RxDoctor Payments Data

Akash Kumar, MD

Gastroenterology · New York, NYNPI 1750708731

Payments from drug & device makers

$135,939in general payments, 2019–2025

Across 162 payments — averaging $839.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$38K
  • E.r. Squibb & Sons, L.L.C.$31K
  • Celltrion USA Inc.$26K
  • Lilly USA, LLC$24K
  • Johnson & Johnson$16K
  • Bristol Myers Squibb$1K
  • plus $790 from 4 others

What the payments were for

  • Consulting fees$7,5556%
  • Speaking & faculty fees$115,01885%
  • Travel & lodging$9,4937%
  • Food & beverage$3,8733%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,939 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$50,320
Medicare patients
175
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab29$799,281
ZeposiaOzanimod Hydrochloride13$113,448
LinzessLinaclotide34$34,313
VoqueznaVonoprazan Fumarate16$9,647
Omeprazole289$3,044
Mesalamine14$2,844
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl155$2,373
Mesalamine DrMesalamine12$2,139
Budesonide EcBudesonide13$1,338
Lactulose36$1,337
Lubiprostone12$873
Famotidine97$832
LoperamideLoperamide Hcl30$678
Pantoprazole Sodium54$648
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$15,772$799,28129 claims
E.r. Squibb & Sons, L.L.C.Zeposia$30,705$113,44813 claims
AbbVieLinzess$58$34,31334 claims
Phathom Pharmaceuticals, Inc.Voquezna$37,747$9,64716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →